Premium Nahrungsergänzungsmittel | artgerecht

K50.0 – Crohn Disease of the Small Intestine

K50.0 is the ICD-10 code for Crohn disease of the small intestine, a chronic inflammatory bowel disease primarily affecting the terminal ileum.

Regular tips about health Regular tips about health

Things worth knowing about "K50.0"

K50.0 is the ICD-10 code for Crohn disease of the small intestine, a chronic inflammatory bowel disease primarily affecting the terminal ileum.

What is K50.0?

The ICD-10 code K50.0 refers to Crohn disease of the small intestine, also known as regional ileitis or terminal ileitis. Crohn disease is a chronic inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract, but under K50.0, the inflammation is located primarily in the small intestine – especially the last section, the terminal ileum. The inflammation is transmural, meaning it affects all layers of the intestinal wall, and the disease follows a relapsing-remitting course.

Causes

The exact cause of Crohn disease is not yet fully understood, but a combination of factors is believed to contribute:

Genetic predisposition: Variants in genes such as NOD2/CARD15 significantly increase the risk of developing the disease.
Immune dysregulation: An abnormal immune response to the normal gut microbiota triggers chronic inflammation.
Microbiome alterations: Changes in the composition of gut bacteria play a contributing role.
Environmental factors: Smoking, a Western-style diet, and hygiene-related factors are discussed as potential triggers.

Symptoms

Common symptoms associated with K50.0 include:

Chronic or recurrent abdominal pain, often in the lower right abdomen
Diarrhea (sometimes bloody or mucous)
Weight loss and reduced appetite
Fatigue and general malaise
Fever during active flares
Extraintestinal manifestations: joint pain, skin lesions (e.g., erythema nodosum), eye inflammation
In children: growth retardation and delayed puberty

Diagnosis

The diagnosis of K50.0 is established through a combination of diagnostic methods:

Endoscopy (ileocolonoscopy): Assessment of the mucosal lining with biopsy; typical findings include segmental inflammation, cobblestone appearance, and aphthous ulcers.
Histology: Detection of granulomas, which are characteristic of Crohn disease.
Imaging: MRI enterography or intestinal ultrasound to assess wall thickening, strictures, and fistulas in the small intestine.
Laboratory tests: Elevated inflammatory markers (CRP, ESR), blood count abnormalities, fecal calprotectin.
Capsule endoscopy: Used in ambiguous cases to visualize the entire small intestinal mucosa.

Treatment

Medical Therapy

Treatment is tailored to disease severity and extent:

Budesonide: First-line corticosteroid for mild to moderate disease of the terminal ileum.
Systemic corticosteroids (e.g., prednisolone): For severe flares.
Immunomodulators (azathioprine, 6-mercaptopurine): Used for maintenance of remission.
Biologics: TNF-alpha inhibitors (e.g., infliximab, adalimumab) or integrin antagonists (vedolizumab) for moderate to severe disease.
JAK inhibitors (e.g., upadacitinib): Newer oral treatment option approved for moderate to severe Crohn disease.

Nutritional Therapy

Exclusive enteral nutrition can be used to induce remission, particularly in children. A well-balanced, nutrient-rich diet is generally important, as malnutrition and deficiencies (e.g., vitamin B12, iron, zinc) are common due to impaired absorption in the small intestine.

Surgical Therapy

Surgery may be necessary for complications such as strictures, fistulas, abscesses, or therapy-refractory disease. Since Crohn disease cannot be cured, surgery aims to remove the affected bowel segment and improve quality of life.

Prognosis and Disease Course

Crohn disease follows a chronic course with alternating flares and remissions. There is currently no cure, but with modern therapeutic approaches, long-term remission can be achieved in many patients. Regular medical follow-up is essential to detect complications early and adjust therapy accordingly.

References

Gomollón F et al. - 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016. Journal of Crohn's and Colitis, 2017; 11(1): 3–25.
Torres J et al. - Crohn's disease. The Lancet, 2017; 389(10080): 1741–1755.
World Health Organization (WHO) - International Classification of Diseases, 10th Revision (ICD-10): Code K50.0.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.